Amneal Pharmaceuticals (AMRX) – Analysts’ Weekly Ratings Updates

A number of firms have modified their ratings and price targets on shares of Amneal Pharmaceuticals (NASDAQ: AMRX) recently:

• 9/23/2026 – Amneal Pharmaceuticals is now covered by Oppenheimer Holdings, Inc.. They set an “outperform” rating and a $27.00 price target on the stock.
• 9/17/2026 – Amneal Pharmaceuticals had its price target raised by Barclays PLC from $16.00 to $20.00. They now have an “overweight” rating on the stock.
• 9/9/2026 – Amneal Pharmaceuticals is now covered by Leerink Partners. They set an “outperform” rating and a $23.00 price target on the stock.
• 9/9/2026 – Amneal Pharmaceuticals is now covered by Leerink Partners. They set an “outperform” rating and a $23.00 price target on the stock.
• 9/7/2026 – Amneal Pharmaceuticals was downgraded by Zacks Research from “strong-buy” to “hold”.
• 8/26/2026 – Amneal Pharmaceuticals was upgraded by Weiss Ratings from “hold (c+)” to “buy (b-)”.
• 8/26/2026 – Amneal Pharmaceuticals had its “overweight” rating reaffirmed by JPMorgan Chase & Co.. They now have a $22.00 price target on the stock.
• 8/12/2026 – Amneal Pharmaceuticals was downgraded by Weiss Ratings from “buy (b-)” to “hold (c+)”.
• 8/7/2026 – Amneal Pharmaceuticals was upgraded by Zacks Research from “hold” to “strong-buy”.
• 8/3/2026 – Amneal Pharmaceuticals had its price target raised by UBS Group AG from $23.00 to $25.00. They now have a “buy” rating on the stock.
• 7/31/2026 – Amneal Pharmaceuticals had its “buy” rating reaffirmed by The Goldman Sachs Group, Inc.. They now have a $21.00 price target on the stock.
• 7/29/2026 – Amneal Pharmaceuticals was upgraded by Weiss Ratings from “hold (c+)” to “buy (b-)”.

Insider Activity

In related news, EVP Nikita Shah sold 146,403 shares of the business’s stock in a transaction on Wednesday, August 12th. The shares were sold at an average price of $17.51, for a total value of $2,563,516.53. Following the sale, the executive vice president directly owned 253,390 shares of the company’s stock, valued at approximately $4,436,858.90. The trade was a 36.62% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, EVP Jason B. Daly sold 210,000 shares of the business’s stock in a transaction that occurred on Wednesday, August 12th. The shares were sold at an average price of $17.40, for a total value of $3,654,000.00. Following the completion of the sale, the executive vice president owned 35,171 shares in the company, valued at $611,975.40. The trade was a 85.65% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 413,016 shares of company stock valued at $7,216,567 in the last quarter. Company insiders own 17.30% of the company’s stock.

Amneal Pharmaceuticals, Inc is a specialty pharmaceutical company that develops, manufactures and commercializes a broad portfolio of generic and specialty medicines. Its products include dosage forms such as tablets, capsules, injectables, ophthalmic products and inhalation therapies, with a focus on complex generics and other products that can be more difficult to develop or manufacture.

The company also markets branded specialty pharmaceuticals in areas including central nervous system disorders, endocrinology, metabolic disease and other therapeutic categories.